MX2013002145A - Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma. - Google Patents
Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma.Info
- Publication number
- MX2013002145A MX2013002145A MX2013002145A MX2013002145A MX2013002145A MX 2013002145 A MX2013002145 A MX 2013002145A MX 2013002145 A MX2013002145 A MX 2013002145A MX 2013002145 A MX2013002145 A MX 2013002145A MX 2013002145 A MX2013002145 A MX 2013002145A
- Authority
- MX
- Mexico
- Prior art keywords
- apolipoprotein
- lipid
- phosphatidylcholine
- tetranectin
- fatty acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
En la presente se reporta una partícula lipídica que comprende una apolipoproteína, una fosfatidilcolina y un lípido, tal como un fosfolípido, ácido graso o un lípido esteroide. En una modalidad, la partícula lipídica comprende únicamente una apolipoproteína. En una modalidad, la partícula lipídica consiste de una apolipoproteína, un fosfolípido, un lípido y un detergente. En una modalidad, el lípido es una segunda fosfatidilcolina, en donde la primera fosfatidilcolina y la segunda fosfatidilcolina difieren en uno o dos residuos de ácido graso o derivados de residuo de ácido graso los cuales están esterificados a la estructura principal de glicerol de la fosfatidilcolina. En una modalidad, la apolipoproteína se selecciona de una apolipoproteína que tiene la secuencia de aminoácidos que se selecciona de la SEC ID NO: 01, 02, 06, 66 y 67, o es una variante de las misma que tiene por lo menos 70 de identidad de secuencia con la secuencia seleccionada.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10008993 | 2010-08-30 | ||
| EP10188392 | 2010-10-21 | ||
| PCT/EP2011/064602 WO2012028526A2 (en) | 2010-08-30 | 2011-08-25 | Tetranectin-apolipoprotein a-i, lipid particles containing it and its use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013002145A true MX2013002145A (es) | 2013-04-03 |
Family
ID=45773308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013002145A MX2013002145A (es) | 2010-08-30 | 2011-08-25 | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9187550B2 (es) |
| EP (1) | EP2611418A2 (es) |
| JP (2) | JP5860052B2 (es) |
| KR (1) | KR101631363B1 (es) |
| CN (1) | CN103108626A (es) |
| AR (1) | AR082644A1 (es) |
| BR (1) | BR112013004395A2 (es) |
| CA (1) | CA2807448A1 (es) |
| MX (1) | MX2013002145A (es) |
| RU (1) | RU2013112562A (es) |
| TW (1) | TW201215394A (es) |
| WO (1) | WO2012028526A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013004395A2 (pt) * | 2010-08-30 | 2019-09-24 | Hoffmann La Roche | tetranectina-apolipoproteína a-i, partículas de lipídio que a contém a sua utilização |
| JP6207507B2 (ja) | 2011-08-25 | 2017-10-04 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 短縮されたテトラネクチン−アポリポプロテインａ−ｉ融合タンパク質、それを含む脂質粒子、及びその使用 |
| EP2748178B1 (en) | 2011-08-25 | 2018-10-31 | F. Hoffmann-La Roche AG | Cation and anion exchange chromatography method |
| US20150044718A1 (en) | 2012-02-29 | 2015-02-12 | Hoffmann-La Roche Inc. | On-column enzymatic cleavage |
| SG11201505916XA (en) * | 2013-02-22 | 2015-09-29 | Hoffmann La Roche | Use of an amino acid auxotrophy cured prokaryotic strain for the recombinant production of a polypeptide |
| AU2016238290B9 (en) * | 2015-03-25 | 2019-06-13 | The Regents Of The University Of Michigan | Compositions and methods for delivery of biomacromolecule agents |
| WO2018223118A1 (en) * | 2017-06-02 | 2018-12-06 | The Feinstein Institute For Medical Research | Use of tetranectin and peptide agonists to treat inflammatory diseases |
| JP2020058343A (ja) * | 2018-10-05 | 2020-04-16 | 東ソー株式会社 | フコース結合性タンパク質の製造方法 |
| CN112546201A (zh) * | 2019-09-26 | 2021-03-26 | 中国科学院生物物理研究所 | 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5733879A (en) * | 1992-06-12 | 1998-03-31 | N.V. Innogenetics, S.A. | Peptides and proteins, process for their preparation and their use as cholesterol acceptors |
| AU736707B2 (en) | 1997-06-11 | 2001-08-02 | Anaphore, Inc. | Trimerising module |
| US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6291245B1 (en) | 1998-07-15 | 2001-09-18 | Roche Diagnostics Gmbh | Host-vector system |
| EP0972838B1 (en) | 1998-07-15 | 2004-09-15 | Roche Diagnostics GmbH | Escherichia coli host/vector system based on antibiotic-free selection by complementation of an auxotrophy |
| EP1276754A4 (en) | 2000-04-14 | 2005-04-06 | Nuvelo Inc | MATERIALS AND METHODS RELATING TO LIPID METABOLISM |
| EP2343317A1 (en) * | 2000-11-10 | 2011-07-13 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
| US7592008B2 (en) * | 2000-11-20 | 2009-09-22 | The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois | Membrane scaffold proteins |
| ITMI20021058A1 (it) * | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
| BR0310099A (pt) * | 2002-05-17 | 2007-03-20 | Esperion Therapeutics Inc | método para tratar dislipidemia ou uma doença associada com a dislipidemia |
| CN1668645A (zh) | 2002-05-17 | 2005-09-14 | 埃斯佩里安医疗公司 | 治疗缺血再灌注的方法和组合物 |
| CA2443365C (en) | 2002-11-19 | 2010-01-12 | F. Hoffmann-La Roche Ag | Methods for the recombinant production of antifusogenic peptides |
| ES2253604T3 (es) | 2003-06-12 | 2006-06-01 | F. Hoffmann-La Roche Ag | Metodo para la produccion recombinante de polipeptidos. |
| PE20050438A1 (es) | 2003-10-20 | 2005-06-14 | Esperion Therapeutics Inc | Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos |
| US20060019870A1 (en) | 2004-01-28 | 2006-01-26 | O'donnell Francis E Jr | Apoprotein cochleate compositions |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| KR100560102B1 (ko) | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
| US8206750B2 (en) * | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| WO2006125304A1 (en) | 2005-05-25 | 2006-11-30 | Liponex, Inc. | Pharmaceutical compositions for treating or preventing coronary artery disease |
| US20070254832A1 (en) | 2006-02-17 | 2007-11-01 | Pressler Milton L | Methods for the treatment of macular degeneration and related eye conditions |
| CN101489577B (zh) | 2006-06-01 | 2013-10-16 | 蒙特利尔心脏病学研究所 | 治疗心瓣膜病的方法和化合物 |
| CA2695951A1 (en) | 2006-08-10 | 2008-02-14 | Plantechno S.R.L. | In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins |
| WO2008094905A2 (en) | 2007-01-29 | 2008-08-07 | Lipid Sciences, Inc. | Encapsulated hdl mimetic peptides |
| EP2118129A4 (en) | 2007-03-01 | 2010-04-28 | Life Technologies Corp | ISOLATED PHOSPHOLIPID PROTEIN PARTICLES |
| AU2008266753A1 (en) * | 2007-06-20 | 2008-12-24 | Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. | ApoA-1 peptide mimetics |
| WO2009036460A2 (en) | 2007-09-14 | 2009-03-19 | Ambrx, Inc. | Modified human apolipoprotein a-i polypeptides and their uses |
| US8999320B2 (en) | 2008-01-30 | 2015-04-07 | The Rockefeller University | Nanoscale bound bilayers, methods of use and production |
| JP5539962B2 (ja) | 2008-04-25 | 2014-07-02 | ノースウェスタン、ユニバーシティ | コレステロールを隔離するのに適したナノ構造体 |
| WO2010083611A1 (en) | 2009-01-23 | 2010-07-29 | Institut De Cardiologie De Montreal | Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex |
| BR112013004395A2 (pt) * | 2010-08-30 | 2019-09-24 | Hoffmann La Roche | tetranectina-apolipoproteína a-i, partículas de lipídio que a contém a sua utilização |
-
2011
- 2011-08-25 BR BR112013004395A patent/BR112013004395A2/pt not_active IP Right Cessation
- 2011-08-25 CN CN2011800419518A patent/CN103108626A/zh active Pending
- 2011-08-25 WO PCT/EP2011/064602 patent/WO2012028526A2/en active Application Filing
- 2011-08-25 US US13/217,534 patent/US9187550B2/en not_active Expired - Fee Related
- 2011-08-25 TW TW100130573A patent/TW201215394A/zh unknown
- 2011-08-25 CA CA2807448A patent/CA2807448A1/en not_active Abandoned
- 2011-08-25 AR ARP110103103A patent/AR082644A1/es unknown
- 2011-08-25 MX MX2013002145A patent/MX2013002145A/es unknown
- 2011-08-25 RU RU2013112562/15A patent/RU2013112562A/ru not_active Application Discontinuation
- 2011-08-25 KR KR1020137007879A patent/KR101631363B1/ko active IP Right Grant
- 2011-08-25 JP JP2013526414A patent/JP5860052B2/ja not_active Expired - Fee Related
- 2011-08-25 EP EP11748408.9A patent/EP2611418A2/en not_active Withdrawn
-
2015
- 2015-10-02 JP JP2015196701A patent/JP2016026186A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2013112562A (ru) | 2014-10-10 |
| WO2012028526A2 (en) | 2012-03-08 |
| CA2807448A1 (en) | 2012-03-08 |
| BR112013004395A2 (pt) | 2019-09-24 |
| US9187550B2 (en) | 2015-11-17 |
| KR20130059428A (ko) | 2013-06-05 |
| TW201215394A (en) | 2012-04-16 |
| JP2016026186A (ja) | 2016-02-12 |
| JP2013540106A (ja) | 2013-10-31 |
| EP2611418A2 (en) | 2013-07-10 |
| JP5860052B2 (ja) | 2016-02-16 |
| WO2012028526A3 (en) | 2012-10-18 |
| AR082644A1 (es) | 2012-12-19 |
| KR101631363B1 (ko) | 2016-06-17 |
| CN103108626A (zh) | 2013-05-15 |
| US20120190610A1 (en) | 2012-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013002145A (es) | Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma. | |
| NZ595856A (en) | Pharmaceutical composition | |
| WO2013075116A3 (en) | Omega 7 rich compositions and methods of isolating omega 7 fatty acids | |
| MX2012014079A (es) | Lipidos biodegradables para la administracion de agentes activos. | |
| BR112014001907A2 (pt) | produção de dha e outros lc-pufas em plantas | |
| AR085845A1 (es) | Composiciones | |
| WO2010057203A3 (en) | Hdl particles for delivery of nucleic acids | |
| EA201171113A1 (ru) | Композиции, содержащие масляную смесь жирных кислот и поверхностно-активное вещество, способы и применения композиций | |
| MX2015000924A (es) | Composiciones liquidas de limpieza con ph bajo con enzimas. | |
| NZ595952A (en) | Antimicrobial compositions and related methods of use | |
| MY141005A (en) | Branched biodiesels | |
| NZ703267A (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| MX2012014928A (es) | Una formulacion de lipoproteina de alta densidad reconstituida y metodo de produccion de la misma. | |
| MX363668B (es) | Generacion enzimatica de lipidos funcionales a partir de cereales o bi-corrientes de cereal. | |
| MY180953A (en) | Acyl-acp thioesterase | |
| WO2012069836A3 (en) | Biologically active complex and its preparation | |
| IN2014MN02355A (es) | ||
| BR112014009376A2 (pt) | composições | |
| EP3760638A3 (en) | Compositions and methods utilizing lysophosphatidylcholine scaffolds | |
| NZ747847A (en) | Lipid compositions | |
| IN2014DN07483A (es) | ||
| WO2012119781A3 (en) | Novel lipids, phospholipids, phospholipid and lipid compositions and their use | |
| WO2012057492A3 (ko) | 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형 | |
| MX364587B (es) | Formulaciones reconstituidas de hdl. | |
| MX2015007082A (es) | Métodos de administración de composiciones que comprenden ácido docosapentanoico. |